Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Edema | Case report

Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report

Authors: Ali Nowrouzi, Sepideh Kafiabasabadi, Mario Rodriguez-Calzadilla, Javier Benitez-del-Castillo, Alejandro Soto-Guerrero, Antonio Diaz-Ramos, Kyara Vaneska Marques-Cavalcante

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

We report our findings in a patient who developed central retinal vein occlusion (CRVO) and was a chronic user of olanzapine, an antipsychotic medication.

Case presentation

A 50-year-old Caucasian man, non-smoker, was referred to our clinic with the chief complaint of floater appearance in his left eye for the past 3 days. His past medical history indicated that he had been taking antipsychotic drugs (olanzapine) for about 3 years, with no other systemic disease or risk factors for CRVO.
In the examination, his best-corrected visual acuity (BCVA) was 0.7 in the left eye. The fundus showed signs of nonischemic CRVO with subhyaloid hemorrhage and intraretinal hemorrhage in the posterior pole and superior and inferior retina, without macular edema, confirmed by optical coherence tomography (OCT).
We ruled out other probable differential diagnoses and risk factors which lead to CRVO through a complete physical exam and blood analysis (complete blood count, glucose, urea, creatinine, lipid profile, erythrocyte sedimentation rate, C-reactive protein, prothrombin time, partial thromboplastin time, Bleeding time (BT), fibrinogen level, proteins, antiphospholipid antibodies, homocysteine blood level, antithrombin III, protein C and S, factor V Leiden, prothrombin mutation, angiotensin-converting enzyme level, other autoantibodies, and human leukocyte antigen [HLA]-B51). Finally, we confirmed the probable side effect of olanzapine in CRVO, which has not been previously reported. A possible pro-thrombogenic mechanism of olanzapine at the molecular level is an affinity for 5-HT2Aserotonin receptors. Blocking these receptors results in increased platelet aggregation and increased blood coagulability.

Conclusions

These results indicate that CRVO can be a complication of chronic use of antipsychotic medications such as olanzapine, as shown for the first time in our case report. Clinicians should question patients who develop a sudden CRVO whether they are using antipsychotic medications such as olanzapine.
Literature
1.
go back to reference Curtin F, Blum M. Antipsychotics and risk of venous thrombosis. Br J Psychiatry. 2002;180:85.CrossRef Curtin F, Blum M. Antipsychotics and risk of venous thrombosis. Br J Psychiatry. 2002;180:85.CrossRef
2.
go back to reference Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677–82.CrossRef Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677–82.CrossRef
3.
go back to reference Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. ThrombHaemost. 2002;88:205–9. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. ThrombHaemost. 2002;88:205–9.
4.
go back to reference Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry. 2001;179:63–6.CrossRef Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry. 2001;179:63–6.CrossRef
5.
go back to reference Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.CrossRef Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.CrossRef
6.
go back to reference Wu CS, Lin CC, Chang CM, Wu KY, Liang HY, Huang YW, et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry. 2013;74:918–24.CrossRef Wu CS, Lin CC, Chang CM, Wu KY, Liang HY, Huang YW, et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry. 2013;74:918–24.CrossRef
7.
go back to reference Taki K, Kida T, Fukumoto M, Sato T, Oku H, Ikeda T. Central retinal vein occlusion in 2 patients using antipsychotic drugs. Case Rep Ophthalmol. 2017;8(2):410–5.CrossRef Taki K, Kida T, Fukumoto M, Sato T, Oku H, Ikeda T. Central retinal vein occlusion in 2 patients using antipsychotic drugs. Case Rep Ophthalmol. 2017;8(2):410–5.CrossRef
8.
go back to reference Fraenkl SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins. EPMA J. 2010;1:253–61.CrossRef Fraenkl SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins. EPMA J. 2010;1:253–61.CrossRef
9.
go back to reference Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. SurvOphthalmol. 2011;56:281–99. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. SurvOphthalmol. 2011;56:281–99.
10.
go back to reference Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J ThrombHaemost. 2010;8:1886–94. CrossRef Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J ThrombHaemost. 2010;8:1886–94. CrossRef
11.
go back to reference McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978;138:216–20. CrossRef McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978;138:216–20. CrossRef
12.
go back to reference Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, Aung T, Wong TY. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92(10):1316–9.CrossRef Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, Aung T, Wong TY. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92(10):1316–9.CrossRef
15.
go back to reference Agca A, Bayraktar Z, Cakr M, Bayraktar S, Ekinci O, Ylmaz OF. Central retinal vein occlusion in a young adult during risperidone therapy. Retin Cases Brief Rep. 2008;2:199–201.CrossRef Agca A, Bayraktar Z, Cakr M, Bayraktar S, Ekinci O, Ylmaz OF. Central retinal vein occlusion in a young adult during risperidone therapy. Retin Cases Brief Rep. 2008;2:199–201.CrossRef
16.
go back to reference Yong KC, Kah TA, Ghee YT, Siang LC, Bastion ML. Branch retinal vein occlusion associated with quetiapine fumarate. BMC Ophthalmol. 2011;11:24.CrossRef Yong KC, Kah TA, Ghee YT, Siang LC, Bastion ML. Branch retinal vein occlusion associated with quetiapine fumarate. BMC Ophthalmol. 2011;11:24.CrossRef
18.
go back to reference Masopust J, Bazantova V, Kuca K, Klimova B, Valis M. Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series. Front Psychiatry. 2019;10:330.CrossRef Masopust J, Bazantova V, Kuca K, Klimova B, Valis M. Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series. Front Psychiatry. 2019;10:330.CrossRef
22.
go back to reference Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci. 1993;53:209–15.CrossRef Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci. 1993;53:209–15.CrossRef
23.
go back to reference Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208:961–72.CrossRef Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208:961–72.CrossRef
24.
go back to reference Mozaffarieh M, Bartschi M, Henrich PB, Schoetzau A, Flammer J. Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions. Graefes Arch ClinExpOphthalmol. 2014;252:1569–71.CrossRef Mozaffarieh M, Bartschi M, Henrich PB, Schoetzau A, Flammer J. Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions. Graefes Arch ClinExpOphthalmol. 2014;252:1569–71.CrossRef
25.
go back to reference Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. EPMA J. 2015;6:21.CrossRef Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. EPMA J. 2015;6:21.CrossRef
Metadata
Title
Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report
Authors
Ali Nowrouzi
Sepideh Kafiabasabadi
Mario Rodriguez-Calzadilla
Javier Benitez-del-Castillo
Alejandro Soto-Guerrero
Antonio Diaz-Ramos
Kyara Vaneska Marques-Cavalcante
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
Edema
Olanzapine
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-02865-8

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue